Investigational drug · Phase 2
TTAX03
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "TTAX03"
First trial start
2021
Dec 6, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TTAX03", any sponsor or status.
Conditions studied
As listed on its trial records.
- Knee Osteoarthritis
- Knee Pain Chronic
- Knee Arthritis
- Dry Eye
- Dry Eye Disease (DED)
- Dry Eye Disease With Severe Keratitis
Approved drugs for the same conditions: Osteoarthritis · Dry eye disease · Ophthalmology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "TTAX03" as an intervention, largest first.
BioTissue Holdings, IncIndustry
NCT05079035 · 90 participants · Start Dec 6, 2021 · Primary completion Mar 7, 2025
Drug: TTAX03; Saline · For: Knee Osteoarthritis; Knee Pain Chronic; Knee Arthritis
Sites: Birmingham, Alabama; Tucson, Arizona; La Mesa, California · 10 sites in all
BioTissue Holdings, IncIndustry
NCT06780306 · 74 participants · Start Dec 12, 2024 · Primary completion Jan 30, 2026
Drug: TTAX03; Saline (NaCl 0,9 %) (placebo) · For: Dry Eye; Dry Eye Disease (DED); Dry Eye Disease With Severe Keratitis
Sites: Berkeley, California; Deerfield Beach, Florida; Chaska, Minnesota · 9 sites in all
BioTissue Holdings, IncIndustry
NCT06236308 · 0 participants · Start Jul 15, 2024 · Primary completion Jan 31, 2025
Drug: TTAX03 10mg; TTAX03 25mg and 1 more · For: Facet Joint Pain
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Knee Osteoarthritis
- EcnoglutideXW003, VRB-101Phase 38 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- JOINTSTEMPhase 32 trials
R-Bio · Knee Osteoarthritis, Osteoarthritis, Knee
- Reference DrugNSAIDsPhase 32 trials
SANGMYUNG innovation · Retinal Vein Occlusion With Macular Edema, Knee Osteoarthritis
- PTP-01MOTYS, allogeneic human placental tissue particulatePhase 31 trial
Doron Therapeutics Inc. · Knee Osteoarthritis
- Human umbilical cord blood-derived mesenchymal stem cellsSMUP-IA-01, mid-dosePhase 22 trials
Medipost Co Ltd. · Knee Osteoarthritis, Bronchopulmonary Dysplasia, BPD
- NCR100Phase 21 trial
Nuwacell Biotechnologies Co., Ltd. · Knee Osteoarthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.